Louis‐David Cantin

Author

Louis‐David Cantin

AstraZeneca (Canada)

Also Known As

L Cantin, L.‐D. CANTIN, Louis-David Cantin, Louis‐David Cantin

Publications

564

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (Canada)Université de Montréal University of Pennsylvania Bayer (Germany)AstraZeneca (Sweden)

About

Louis‐David Cantin is an author at AstraZeneca (Canada) specializing in pharmacology, medicine, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	290
2	Biochemistry	9	9	290
3	Natural Sciences	7	7	244
4	Health Sciences	1	1	30
5	Biomolecular Engineering	1	1	55

Louis‐David Cantin

Publications

553

Citations

H-Index

Page 1

	Year	Citations
Mitigating the Inhibition of Human Bile Salt Export Pump by Drugs: Opportunities Provided by Physicochemical Property Modulation, In Silico Modeling, and Structural Modification Daniel J. Warner, Hongming Chen, Louis‐David Cantin, Drug Metabolism and Disposition	2012	84
Design, Synthesis, and Biological Evaluation of Monopyrrolinone-Based HIV-1 Protease Inhibitors Amos B. Smith, Louis‐David Cantin, Alexander Pasternak, Journal of Medicinal Chemistry	2003	61
Development of a Computational Tool to Rival Experts in the Prediction of Sites of Metabolism of Xenobiotics by P450s Valérie Campágna‐Slater, Joshua Pottel, Éric Therrien, Journal of Chemical Information and Modeling Computational ToolChemical BiologyMetabolic ModelObserved SomTransition States	2012	57
Virtual Screening and Computational Optimization for the Discovery of Covalent Prolyl Oligopeptidase Inhibitors with Activity in Human Cells Stéphane De Cesco, Sébastien Deslandes, Éric Therrien, Journal of Medicinal Chemistry Covalent InhibitorsDrug TargetPeptide ScienceChemical BiologyMolecular Pharmacology	2012	55
The synthesis of enantiomerically pure, symmetrically substituted cyclopropane phosphonic acids — A constrained analog of the GABA antagonist phaclophen Stephen Hanessian, Louis‐David Cantin, Stéphan Roy, Tetrahedron Letters Constrained AnalogBioorganic ChemistryGaba Antagonist PhaclophenBiochemistryNatural Sciences	1997	52
The synthesis of enantiomerically pure disubstituted aziridines and N-alkoxy aziridines Stephen Hanessian, Louis‐David Cantin Tetrahedron Letters N-alkoxy AziridinesOrganic ChemistryStereoselective SynthesisPharmacologySynthetic Chemistry	2000	38
In vitro evaluation of the activities of azithromycin alone and combined with pyrimethamine against Toxoplasma gondii Louis‐David Cantin, Suzanne Chamberland Antimicrobial Agents and Chemotherapy Drug InteractionAntibioticsAntiparasitic AgentMedicineVitro Microassay	1993	37
PDE-10A inhibitors as insulin secretagogues Louis‐David Cantin, Steven Magnuson, David Gunn, Bioorganic & Medicinal Chemistry Letters BiochemistryPde-10a InhibitorsMedicineInsulin ManagementDiabetes	2007	35
Discovery of P2X3 selective antagonists for the treatment of chronic pain Louis‐David Cantin, Malken Bayrakdarian, Christophe Buon, Bioorganic & Medicinal Chemistry Letters Pain TherapyHealth SciencesPain MedicineP2x3 Selective AntagonistsPain Treatment	2012	30
Design and synthesis of MMP inhibitors using N -arylsulfonylaziridine hydroxamic acids as constrained scaffolds Stephen Hanessian, Nicolas Moitessier, Louis‐David Cantin Tetrahedron Combinatorial ChemistryMedicinal ChemistryConstrained ScaffoldsBiochemistryMedicine	2001	22

Page 1